Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > DE PLANE BOSS, DE PLANE

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Aug 25, 2022 5:33pm

116 Views

Post# 34921065

RE:RE:RE:RE:DE PLANE BOSS, DE PLANE

And once again you prove my point that you are not interested in any opinon other than your own. You only want to make false accusations and attempt to demean others. You have not interested in a serious conversation.

I sent you a PM with my ph number call me if you are interested in a genuine conversation.

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management